<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771574</url>
  </required_header>
  <id_info>
    <org_study_id>36673</org_study_id>
    <nct_id>NCT02771574</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia</brief_title>
  <official_title>A Phase 2 Multi-Ascending Dose Trial to Assess the Efficacy, Tolerability and Pharmacokinetic Profile of Exendin (9-39) in Patients With Post-bariatric Hyperinsulinemic Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tracey McLaughlin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy, safety and pharmacokinetics of subcutaneous&#xD;
      exendin (9-39) in subjects with post-bariatric hypoglycemia. Development of this subcutaneous&#xD;
      formulation of exendin (9-39) would represent a targeted therapeutic approach for this rare&#xD;
      disease with unmet clinical need.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-Bariatric Hypoglycemia (PBH) is a rare, but increasingly reported disease occurring&#xD;
      after bariatric surgery, characterized by severe hypoglycemic episodes accompanied by&#xD;
      symptoms of hypoglycemia. At the moment, no medical therapies have been developed for this&#xD;
      disorder, but the clinical need is great. The major contributory factor is thought to be an&#xD;
      exaggerated secretion of glucagon-like peptide-1 (GLP-1) due to altered nutrient transit&#xD;
      after bariatric surgery. GLP-1 is an incretin hormone secreted primarily by the distal ileum&#xD;
      that contributes to postprandial glucose regulation. Exendin (9-39) is a specific GLP-1&#xD;
      receptor antagonist, that when given via continuous IV infusion, has been shown to&#xD;
      effectively prevent postprandial hypoglycemia and reduce symptoms of hypoglycemia in patients&#xD;
      with PBH. This study is designed to assess the efficacy, safety and pharmacokinetic profile&#xD;
      of a novel subcutaneous formulation of exendin (9-39).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nadir Glucose</measure>
    <time_frame>Day 3 (time zero then every 30 minutes until 180 minutes or gylcemic rescue was required)</time_frame>
    <description>Nadir glucose at baseline and at Day 3 of treatment during oral glucose tolerance test (OGTT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Composite Symptom Score as a Measure of Treatment Effect</measure>
    <time_frame>Baseline, Day 3</time_frame>
    <description>Symptoms of hypoglycemia were assessed using the Edinburgh Hypoglycemia Symptom Scale that measures the intensity of 13 commonly experienced hypoglycemic symptoms, each severity graded on a 6-point Likert scale (0 = not present, 5 = severe). Scores are summed for a composite score ranging from 0 to 65, with higher scores corresponding to more severe hypoglycemia symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Subcutaneous Avexitide: Plasma Concentration Prior to Dosing (Co)</measure>
    <time_frame>Day 3 (Predose)</time_frame>
    <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Subcutaneous Avexitide: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose)</time_frame>
    <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Subcutaneous Avexitide: Time of Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose)</time_frame>
    <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Subcutaneous Avexitide: Area Under the Plasma Concentration Versus Time Curve (AUC)</measure>
    <time_frame>Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose)</time_frame>
    <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Post Bariatric Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Part A: Lyo avexitide 0.05 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Lyo avexitide 0.15 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Lyo avexitide twice daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Lyo avexitide 0.35 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Lyo avexitide twice daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Lyo avexitide 0.46 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Lyo avexitide twice daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Liq avexitide 0.38 (±0.03) mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lyo avexitide</intervention_name>
    <description>Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)</description>
    <arm_group_label>Part A: Lyo avexitide 0.05 mg/kg</arm_group_label>
    <arm_group_label>Part A: Lyo avexitide 0.15 mg/kg</arm_group_label>
    <arm_group_label>Part A: Lyo avexitide 0.35 mg/kg</arm_group_label>
    <arm_group_label>Part A: Lyo avexitide 0.46 mg/kg</arm_group_label>
    <other_name>Exendin (9-39)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liq avexitide</intervention_name>
    <description>Liquid avexitide (Liq avexitide) administered subcutaneously (sc)</description>
    <arm_group_label>Part B: Liq avexitide 0.38 (±0.03) mg/kg</arm_group_label>
    <other_name>Exendin (9-39)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post-bariatric surgery more than 6 months prior to signing the informed consent&#xD;
&#xD;
          -  Reported history of Whipple's triad: the occurrence of hypoglycemic symptoms&#xD;
             associated with a capillary blood glucose of ≤55 mg/dL, and resolution with glucose or&#xD;
             carbohydrate administration.&#xD;
&#xD;
          -  Symptomatic hypoglycemia during the baseline/screening oral glucose tolerance test&#xD;
             (OGTT), as defined by the presence of plasma glucose ≤55 mg/dL with concomitant&#xD;
             autonomic and/or neuroglycopenic symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients currently using sulfonylureas or other medications that may interfere with&#xD;
             glucose metabolism within 5 half-lives of drug.&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 weeks prior to dosing&#xD;
&#xD;
          -  History of or current insulinoma&#xD;
&#xD;
          -  Active infection or significant acute illness within 2 weeks prior to dosing&#xD;
&#xD;
          -  Female patients who are pregnant or lactating&#xD;
&#xD;
          -  Women of childbearing potential and not utilizing effective contraceptive methods&#xD;
&#xD;
          -  Inadequate end organ function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marilyn Tan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Assistant Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tan M, Lamendola C, Luong R, McLaughlin T, Craig C. Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) for treatment of post-bariatric hypoglycaemia. Diabetes Obes Metab. 2020 Aug;22(8):1406-1416. doi: 10.1111/dom.14048. Epub 2020 May 4.</citation>
    <PMID>32250530</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <results_first_submitted>June 6, 2020</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2020</results_first_posted>
  <disposition_first_submitted>June 28, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 29, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 5, 2018</disposition_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Tracey McLaughlin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine (Endocrinology)</investigator_title>
  </responsible_party>
  <keyword>Bariatric surgery complications</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Exendin (9-39)</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02771574/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02771574/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A: Lyo Avexitide 0.5 mg/kg</title>
          <description>Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc) twice daily for 3 days</description>
        </group>
        <group group_id="P2">
          <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="P3">
          <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="P4">
          <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="P5">
          <title>Part B: Liq Avexitide 0.38 (±0.03) mg/kg</title>
          <description>Liquid avexitide (Liq avexitide) administered sc twice daily for 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Lyo Avexitide Dose Level 1 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Lyo Avexitide Dose Level 2 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Lyo Avexitide Dose Level 3 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Lyo Avexitide Dose Level 4 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Liq Avexitide (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: Lyo Avexitide 0.05 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="B2">
          <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="B3">
          <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="B4">
          <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="B5">
          <title>Part B: Liq Avexitide 0.38 mg/kg</title>
          <description>Liq avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="14.1"/>
                    <measurement group_id="B2" value="50.2" spread="12.7"/>
                    <measurement group_id="B3" value="41.3" spread="14.6"/>
                    <measurement group_id="B4" value="44.7" spread="10.6"/>
                    <measurement group_id="B5" value="48.0" spread="13.8"/>
                    <measurement group_id="B6" value="46.7" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nadir Glucose</title>
        <description>Nadir glucose at baseline and at Day 3 of treatment during oral glucose tolerance test (OGTT).</description>
        <time_frame>Day 3 (time zero then every 30 minutes until 180 minutes or gylcemic rescue was required)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A: Lyo Avexitide 0.5 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Part A: Lyo Avexitide 0.35 mg/kg and 0.46 mg/kg Groups</title>
            <description>Lyo avexitide administered sc twice daily for 3 days&#xD;
This reporting group is a pooled analysis of data from the Part A: Lyo avexitide 0.35 mg/kg and 0.46 mg/kg groups.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Liq Avexitide 0.38 (±0.03) mg/kg</title>
            <description>Liq avexitide administered sc twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Nadir Glucose</title>
          <description>Nadir glucose at baseline and at Day 3 of treatment during oral glucose tolerance test (OGTT).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="5"/>
                    <measurement group_id="O2" value="43" spread="7"/>
                    <measurement group_id="O3" value="39" spread="7"/>
                    <measurement group_id="O4" value="42" spread="4"/>
                    <measurement group_id="O5" value="41" spread="5"/>
                    <measurement group_id="O6" value="41" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="6"/>
                    <measurement group_id="O2" value="46" spread="12"/>
                    <measurement group_id="O3" value="51" spread="3"/>
                    <measurement group_id="O4" value="59" spread="14"/>
                    <measurement group_id="O5" value="55" spread="10"/>
                    <measurement group_id="O6" value="60" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Composite Symptom Score as a Measure of Treatment Effect</title>
        <description>Symptoms of hypoglycemia were assessed using the Edinburgh Hypoglycemia Symptom Scale that measures the intensity of 13 commonly experienced hypoglycemic symptoms, each severity graded on a 6-point Likert scale (0 = not present, 5 = severe). Scores are summed for a composite score ranging from 0 to 65, with higher scores corresponding to more severe hypoglycemia symptoms.</description>
        <time_frame>Baseline, Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A: Lyo Avexitide 0.5 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Part A: Lyo Avexitide 0.35 mg/kg and 0.46 mg/kg Groups</title>
            <description>Lyo avexitide administered sc twice daily for 3 days&#xD;
This reporting group is a pooled analysis of data from the Part A: Lyo avexitide 0.35 mg/kg and 0.46 mg/kg groups.</description>
          </group>
          <group group_id="O6">
            <title>Part B: Liq Avexitide 0.38 (±0.03) mg/kg</title>
            <description>Liq avexitide administered sc twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Composite Symptom Score as a Measure of Treatment Effect</title>
          <description>Symptoms of hypoglycemia were assessed using the Edinburgh Hypoglycemia Symptom Scale that measures the intensity of 13 commonly experienced hypoglycemic symptoms, each severity graded on a 6-point Likert scale (0 = not present, 5 = severe). Scores are summed for a composite score ranging from 0 to 65, with higher scores corresponding to more severe hypoglycemia symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="7"/>
                    <measurement group_id="O2" value="12" spread="4"/>
                    <measurement group_id="O3" value="22" spread="13"/>
                    <measurement group_id="O4" value="15" spread="1"/>
                    <measurement group_id="O5" value="19" spread="9"/>
                    <measurement group_id="O6" value="17" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="11"/>
                    <measurement group_id="O2" value="12" spread="9"/>
                    <measurement group_id="O3" value="15" spread="11"/>
                    <measurement group_id="O4" value="7" spread="3"/>
                    <measurement group_id="O5" value="11" spread="8"/>
                    <measurement group_id="O6" value="9" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Subcutaneous Avexitide: Plasma Concentration Prior to Dosing (Co)</title>
        <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
        <time_frame>Day 3 (Predose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A: Lyo Avexitide 0.05 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Part B: Liq Avexitide 0.38 (±0.03) mg/kg</title>
            <description>Liq avexitide administered sc twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Subcutaneous Avexitide: Plasma Concentration Prior to Dosing (Co)</title>
          <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="7"/>
                    <measurement group_id="O2" value="16" spread="11"/>
                    <measurement group_id="O3" value="4" spread="2"/>
                    <measurement group_id="O4" value="71" spread="62"/>
                    <measurement group_id="O5" value="204" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Subcutaneous Avexitide: Maximum Plasma Concentration (Cmax)</title>
        <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
        <time_frame>Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A: Lyo Avexitide 0.05 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Part B: Liq Avexitide 0.38 (±0.03) mg/kg</title>
            <description>Liq avexitide administered sc twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Subcutaneous Avexitide: Maximum Plasma Concentration (Cmax)</title>
          <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="21"/>
                    <measurement group_id="O2" value="156" spread="54"/>
                    <measurement group_id="O3" value="228" spread="57"/>
                    <measurement group_id="O4" value="331" spread="125"/>
                    <measurement group_id="O5" value="359" spread="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Subcutaneous Avexitide: Time of Maximum Plasma Concentration (Tmax)</title>
        <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
        <time_frame>Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A: Lyo Avexitide 0.05 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Part B: Liq Avexitide 0.38 (±0.03) mg/kg</title>
            <description>Liq avexitide administered sc twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Subcutaneous Avexitide: Time of Maximum Plasma Concentration (Tmax)</title>
          <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" spread="30"/>
                    <measurement group_id="O2" value="252" spread="16"/>
                    <measurement group_id="O3" value="240" spread="60"/>
                    <measurement group_id="O4" value="190" spread="46"/>
                    <measurement group_id="O5" value="396" spread="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Subcutaneous Avexitide: Area Under the Plasma Concentration Versus Time Curve (AUC)</title>
        <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
        <time_frame>Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A: Lyo Avexitide 0.05 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
            <description>Lyo avexitide administered sc twice daily for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Part B: Liq Avexitide 0.38 (±0.03) mg/kg</title>
            <description>Liq avexitide administered sc twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Subcutaneous Avexitide: Area Under the Plasma Concentration Versus Time Curve (AUC)</title>
          <description>Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing.</description>
          <units>ng/mL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21151" spread="9877"/>
                    <measurement group_id="O2" value="51765" spread="2134"/>
                    <measurement group_id="O3" value="77849" spread="23670"/>
                    <measurement group_id="O4" value="129427" spread="31325"/>
                    <measurement group_id="O5" value="147417" spread="57722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three (3) days per treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A: Lyo Avexitide 0.05 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="E2">
          <title>Part A: Lyo Avexitide 0.15 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="E3">
          <title>Part A: Lyo Avexitide 0.35 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="E4">
          <title>Part A: Lyo Avexitide 0.46 mg/kg</title>
          <description>Lyo avexitide administered sc twice daily for 3 days</description>
        </group>
        <group group_id="E5">
          <title>Part B: Liq Avexitide 0.38 (±0.03) mg/kg</title>
          <description>Liq avexitide administered sc twice daily for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cindy Lamendola</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-723-3141</phone>
      <email>clamendola@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

